BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of methylphenidate after oral administration of immediate and sustained-release preparations in Beagle dogs. 2011

E Lavy, and U Prise, and G Soldani, and D Neri, and N Brandriss, and A Bar Chaim, and M Giorgi
School of Veterinary Medicine, Hebrew University of Jerusalem, PO Box 12, Rehovot 76100, Israel.

Methylphenidate (MPH) is a drug administered either as an immediate- or sustained-release preparation for the treatment of attention deficit hyperactivity disorder in humans. The aim of this study was to determine the pharmacokinetics of two different MPH formulations in the dog. Eight dogs were randomly assigned to two treatment groups using a two-part randomised, cross-over experimental design. Each subject received a single dose of 20 mg d,l-MPH as an immediate- (IR) or sustained-release (SR) tablet. Blood was collected at specific times, and the plasma concentrations of d,l-MPH were evaluated using high performance liquid chromatography. There were no adverse effects following the oral administration of d,l-MPH in either the IR or SR groups, apart from mild hyperkinesia which was observed in some of the IR group. The plasma concentration data of d,l-MPH were best described by a one-compartment model. There were significant differences in the maximum concentration (C(max)), time to C(max) (T(max)), area under the curve (AUC) and clearance (Cl) between the two formulations. The relative bioavailability of the SR formulation was 30.58±13.73% and, despite low drug plasma concentrations, the SR formulation resulted in uniform plasma concentrations of d,l-MPH. However, the dose rate of the SR formulation used in this study resulted in plasma concentrations that were below effective levels for clinical efficacy, so further studies are required to confirm the suitability of higher dose rates for clinical use.

UI MeSH Term Description Entries
D008297 Male Males
D008774 Methylphenidate A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE. Centedrin,Concerta,Daytrana,Equasym,Metadate,Methylin,Methylphenidate Hydrochloride,Phenidylate,Ritalin,Ritalin-SR,Ritaline,Tsentedrin,Hydrochloride, Methylphenidate,Ritalin SR
D010375 Pedigree The record of descent or ancestry, particularly of a particular condition or trait, indicating individual family members, their relationships, and their status with respect to the trait or condition. Family Tree,Genealogical Tree,Genealogic Tree,Genetic Identity,Identity, Genetic,Family Trees,Genealogic Trees,Genealogical Trees,Genetic Identities,Identities, Genetic,Tree, Family,Tree, Genealogic,Tree, Genealogical,Trees, Family,Trees, Genealogic,Trees, Genealogical
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

E Lavy, and U Prise, and G Soldani, and D Neri, and N Brandriss, and A Bar Chaim, and M Giorgi
Pharmacokinetics and Pharmacodynamics of Immediate- and Modified-Release Mycophenolic Acid Preparations in Healthy Beagle Dogs.
January 2020, Frontiers in veterinary science,
E Lavy, and U Prise, and G Soldani, and D Neri, and N Brandriss, and A Bar Chaim, and M Giorgi
Toxicity and Pharmacokinetics of Sustained-Release Dexamethasone in Beagle Dogs.
January 2016, Advances in therapy,
E Lavy, and U Prise, and G Soldani, and D Neri, and N Brandriss, and A Bar Chaim, and M Giorgi
Pharmacokinetics of fluconazole after oral administration to healthy beagle dogs.
December 2022, Veterinary dermatology,
E Lavy, and U Prise, and G Soldani, and D Neri, and N Brandriss, and A Bar Chaim, and M Giorgi
Pharmacokinetics of Huperzine A after transdermal and oral administration in beagle dogs.
May 2008, International journal of pharmaceutics,
E Lavy, and U Prise, and G Soldani, and D Neri, and N Brandriss, and A Bar Chaim, and M Giorgi
Stereoselective pharmacokinetics of bisoprolol after intravenous and oral administration in beagle dogs.
May 1997, Journal of pharmaceutical sciences,
E Lavy, and U Prise, and G Soldani, and D Neri, and N Brandriss, and A Bar Chaim, and M Giorgi
[Pharmacokinetics and bioavailabilities of geniposide in Beagle dogs after oral administration Xingnaojing].
August 2012, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,
E Lavy, and U Prise, and G Soldani, and D Neri, and N Brandriss, and A Bar Chaim, and M Giorgi
Pharmacokinetics of Sustained-release, Oral, and Subcutaneous Meloxicam over 72 Hours in Male Beagle Dogs.
November 2020, Journal of the American Association for Laboratory Animal Science : JAALAS,
E Lavy, and U Prise, and G Soldani, and D Neri, and N Brandriss, and A Bar Chaim, and M Giorgi
Preparation and pharmacokinetics in beagle dogs of ganershu sustained-release pellets.
July 2014, Pharmacognosy magazine,
E Lavy, and U Prise, and G Soldani, and D Neri, and N Brandriss, and A Bar Chaim, and M Giorgi
Pharmacokinetics of multiparticulate sustained-release diltiazem preparations in dogs.
January 1994, Journal of pharmaceutical sciences,
E Lavy, and U Prise, and G Soldani, and D Neri, and N Brandriss, and A Bar Chaim, and M Giorgi
Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation.
October 1986, International journal of clinical pharmacology, therapy, and toxicology,
Copied contents to your clipboard!